Patents Assigned to QR PHARMA, Inc.
  • Publication number: 20200237722
    Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 30, 2020
    Applicant: QR PHARMA, Inc.
    Inventor: Maria Maccecchini
  • Publication number: 20190381007
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Application
    Filed: July 8, 2019
    Publication date: December 19, 2019
    Applicant: QR PHARMA, INC.
    Inventor: Maria Maccecchini
  • Patent number: 10383851
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignee: QR PHARMA, INC.
    Inventor: Maria Maccecchini
  • Publication number: 20180338950
    Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.
    Type: Application
    Filed: May 23, 2018
    Publication date: November 29, 2018
    Applicant: QR PHARMA, INC.
    Inventor: Maria Maccecchini
  • Publication number: 20170304266
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Application
    Filed: March 6, 2017
    Publication date: October 26, 2017
    Applicant: QR PHARMA, Inc.
    Inventor: Maria Maccecchini